Drugs / Sinopharm
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05686161 Comparator | Oct → Dec 2022 | — | Stemirna Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sinopharm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05686161 ↗ |
| Known as | BIBP | “Sinopharm (BIBP);SARS-Cov-2.” NCT05686161 ↗ |
| Modality | Vaccine | “COVID-19 Inactivated vaccine” NCT05686161 ↗ |
| Route | Intramuscular | “Route of Administration: injection Intramuscular” NCT05686161 ↗ |